Sowing seeds of confusion again are we ? Totally ignoring the meta data on Grade D survival are we? The up-date from Kurtzberg at the Tandem meeting incorporates data reconciling those who died from both their primary disease and those who died from Chronic as well. Have you seen the comparatives for Ruxolitinib regarding overall survival after 2 years for those with Chronic…I guess not. The graphs are pretty straightforward….and the data and comments have been presented in 2023…by you are quite right about one thing …Mesoblast also reported to the FDA on EAP patient data from several years ago, which is when the last treated patient is accounted for from EAP275. They will have likely made substantial improvements in manufacturing, potency and sera free production since that time…so i accept your point that these results probably do not do justice to what the improved Ryoncil might be capable of. By the way you realise that non malignant sr aGVHD has a very poor prognosis but Ryoncil performs strongly in that subset of patients too ! No cancer relapse there. I will let the graphs above do the talking….unless you can provide any source of material showing better results than these in Grade C/D. Over to you Doc ! OP
Results:There were 51 evaluable patients, including 6 (12%) with Grade B, 22 (43%) with Grade C and 23 (45%) with Grade D SR-aGVHD. Overall, 1-year OS was 63% (95% confidence interval [CI] 49-75), 2-year OS was 51% (95% CI 37-64%) and 3- and 4-year OS was 49% (95% CI 35-62) (Figure 1). At 4 years, probability estimates of OS were 50% (95% CI, 14-86), 48% (95% CI, 28-69), and 48% (95% CI, 28-68) for patients with Grades B, C, and D, respectively (Figure 2). Overall, 8 patients (16%) died from organ failure, 7 (14%) from GVHD (6 from acute and 1 from chronic disease) and 6 (12%) from their primary disease. Three (14%) patients with Grade C and 3 (13%) patients with Grade D aGVHD died due to their primary disease; no patients with Grade B disease died due to their primary disease.
Disclaimer: see footnote to last post.
MSB Price at posting:
$1.19 Sentiment: Buy Disclosure: Held
(20min delay)
